BPC-157 for Gut Healing & Leaky Gut

Candidate profile

Adults with documented or suspected increased intestinal permeability — elevated serum zonulin, positive lactulose-mannitol test, or clinical picture consistent with intestinal barrier dysfunction: multiple food sensitivities, chronic bloating, post-meal fatigue, and systemic inflammation markers (elevated hs-CRP) without another identified source. Also appropriate for individuals recovering from NSAID-induced gastric or intestinal injury, post-infectious gut dysfunction, or as adjunctive support alongside gastroenterological care for inflammatory bowel disease.

This use case is distinct from BPC-157 for tendon recovery — the mechanism is the same peptide but the route, rationale, and monitoring differ substantially.

Approach

Oral BPC-157 administration to deliver the peptide directly to the gastrointestinal mucosa. BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from human gastric juice protein that has demonstrated gastrointestinal protective effects across dozens of preclinical models: gastric ulcer healing, intestinal anastomosis repair, esophageal damage recovery, and prevention of NSAID-induced gut lesions. The oral route places BPC-157 at the site of action — the intestinal epithelium — where it promotes mucosal healing, angiogenesis at injury sites (via VEGFR2 upregulation), and tight junction protein preservation.

Protocol design

Primary peptide: BPC-157, 250-500 mcg per dose

Route: Oral (capsule, stable in gastric acid — BPC-157 is notably acid-resistant for a peptide). Subcutaneous administration is an alternative but delivers the peptide systemically rather than to the gut lumen directly.

Frequency: Twice daily

Timing: On an empty stomach — morning (30 minutes before breakfast) and evening (2+ hours after last meal). Empty stomach maximizes mucosal contact time and avoids competition with food-derived peptides.

Duration: 6-8 weeks. Mucosal healing and tight junction remodeling require sustained exposure. Four weeks is the minimum for measurable permeability changes.

Optional addition — KPV: 500 mcg-1 mg oral, once daily. KPV inhibits NF-kB in colonocytes via PepT1-mediated transport, addressing the inflammatory driver of barrier dysfunction while BPC-157 addresses the structural repair. The combination targets both cause (inflammation) and consequence (mucosal damage).

Optional addition — L-glutamine: 5-10 g daily. Glutamine is the primary metabolic fuel for enterocytes and supports epithelial cell proliferation. This is a nutritional foundation rather than a peptide protocol addition.

Mechanism summary

BPC-157's gastrointestinal effects operate through multiple pathways:

• Angiogenesis: Upregulates VEGFR2 and promotes new blood vessel formation at damaged mucosal sites, improving nutrient and oxygen delivery to healing tissue
• Growth factor modulation: Increases local expression of EGF (epidermal growth factor) receptor and GH receptor, both of which drive epithelial cell proliferation
• Nitric oxide system: Modulates the NO system to maintain mucosal blood flow and reduce ischemic damage
• Tight junction preservation: Preclinical evidence suggests BPC-157 maintains claudin and occludin expression under inflammatory or NSAID-induced stress, preventing paracellular permeability increases
• Anti-inflammatory: Reduces pro-inflammatory cytokine signaling (TNF-alpha, IL-6) in intestinal tissue, which indirectly preserves tight junction integrity

Expected timeline

Week 1-2: Reduction in acute GI symptoms — bloating, post-meal discomfort, and abdominal distension often improve first. These reflect reduced mucosal inflammation rather than completed structural repair.

Week 3-4: Progressive improvement in food tolerance. Foods that previously triggered reactions (bloating, fatigue, loose stool) may become better tolerated as barrier function improves and fewer undigested antigens access the lamina propria. Stool consistency typically stabilizes.

Week 5-8: Measurable changes in intestinal permeability markers. If baseline zonulin was elevated, a downward trend should be evident. Lactulose-mannitol ratio (if tested) should improve. Systemic inflammation markers (hs-CRP) may decrease as reduced endotoxin translocation lowers the chronic inflammatory burden. Subjective quality of life improvements — broader dietary tolerance, reduced brain fog, improved energy — typically consolidate during this phase.

Monitoring

• Serum zonulin at baseline and week 8 (intestinal permeability marker)
• Lactulose-mannitol ratio at baseline and week 8 (functional permeability test, if available)
• hs-CRP at baseline and week 8 (systemic inflammation)
• Food sensitivity symptom diary — daily log of reactions to previously problematic foods
• Bristol stool scale — daily tracking
• Subjective energy and cognitive clarity — weekly self-rating (1-10 scale)

When to stop or reassess

• No GI symptom improvement by week 4: Reassess whether the primary issue is barrier dysfunction vs. dysbiosis (SIBO, fungal overgrowth), motility disorder, or food allergy (IgE-mediated, which barrier repair will not address). Consider comprehensive stool analysis or SIBO breath testing.
• Worsening symptoms: Rare with BPC-157, but if symptoms worsen, consider that improved barrier function may alter the gut microbiome environment. Reassess and consider microbiome-directed interventions.
• Concurrent NSAID use: If the patient continues NSAID use during the protocol, BPC-157 may provide protective effects but cannot fully counteract ongoing NSAID-induced damage. Address the source of injury.

Evidence reality check

BPC-157 has the most extensive preclinical gastrointestinal evidence of any peptide in the research space. Dozens of animal studies demonstrate gastric ulcer healing, intestinal lesion repair, protection against NSAID toxicity, improved anastomosis healing, and reduced inflammatory markers in colitis models. The gastric acid stability is confirmed — unusual and advantageous for oral peptide delivery. However, no controlled human clinical trial has validated these findings for intestinal permeability or "leaky gut." The biological rationale is strong and the preclinical evidence is reproducible across multiple research groups, but the leap from rodent GI physiology to human intestinal barrier disease awaits clinical confirmation.